/** blogpostTitle: Shree Ganesh Remedies Q4 FY26: A Better Quarter, A Consolidation Year, and a CRAMS Inflection Setup */

Shree Ganesh Remedies Q4 FY26: A Better Quarter, A Consolidation Year, and a CRAMS Inflection Setup

Shree Ganesh Remedies Limited closed Q4 FY26 with a sharper quarterly rebound, even as the full year remained largely a consolidation. Revenue from operations in Q4 FY26 rose to INR 33.20 crore, up 36 percent year on year and 57 percent sequentially. EBITDA (excluding other income and exceptional items) increased to INR 11.37 crore, with a margin of 34.3 percent. Profit after tax came in at INR 6.27 crore, down 5 percent year on year but up 103 percent quarter on quarter.

For FY26, however, the company’s topline stayed almost flat. Revenue from operations was INR 109.29 crore versus INR 108.60 crore in FY25. EBITDA for the year declined to INR 35.02 crore from INR 39.21 crore, and PAT fell to INR 17.77 crore from INR 23.10 crore. Management’s explanation was consistent through the year: FY26 was planned as a period of consolidation, focused more on approvals, product development, and capability build-out than on immediate topline acceleration.

Q4 rebound was real, but FY26 shows why the company called it a consolidation year

Management attributed the Q4 sequential recovery to improved execution and a rebound from deferred shipments that had impacted Q3 FY26. Still, the operating environment described by the company remained difficult. It cited a persistent slowdown in Europe, uncertainty from ongoing war-related geopolitical tensions, volatility in raw material markets, and customer purchase deferrals.

Margins were also a central discussion point. Q4 EBITDA margin at 34.3 percent was below Q4 FY25’s 40.4 percent but higher than Q3 FY26’s 31.9 percent. For the full year, EBITDA margin reduced to 32.0 percent from 36.1 percent in FY25. In the earnings call, management stated that the sustainable long-term EBITDA margin range is typically 26 to 28 percent, with periods of higher margins possible during early phases of customer approvals and initial commercialisation.

CRAMS milestone: pilot trials completed, commercial trials next

The most meaningful strategic update was around the company’s contract development and manufacturing engagements. Management stated that Shree Ganesh Remedies has been progressing on CRAMS projects spanning agrochemicals, pharmaceuticals, and electronic applications, with customers in Europe and Japan.

In Q4 FY26, the company said it successfully completed pilot trials for these projects. The next step is commercial trials, and then commercial production, subject to customer and regulatory approvals. Management repeatedly highlighted that approvals and registrations at the customer and end-market level can shift timelines. It also pointed to geopolitical developments as a factor that can prolong regulatory processes.

This is important because FY26 contribution from new CRAMS projects was described as not significant, with pilots still ongoing. The investment case, therefore, rests on the transition from pilot trials into commercial trials and eventual commercial production through FY27 and beyond.

Capacity build-out: Block 7 and the pilot facility as growth enablers

Capacity additions at Ankleshwar are positioned as the near-term backbone for growth. The company stated that its Block 7 expansion program remains on track, and it expects commercial production to commence from Q2 FY27. The investor presentation also references Block 7 commissioning in H1 FY27.

Block 7 is described as being purpose-built for niche, application-led molecules, including the pipeline of CRAMS molecules. The company also indicated that Block 8, added earlier, is still ramping and was operating at roughly 50 percent utilisation, with an expectation to reach full utilisation by the end of FY27.

In addition to manufacturing blocks, the pilot facility is a recurring theme in the company’s narrative. The investor presentation describes a pilot plant designed to bridge R&D and commercial scale-up, and also function as a flexible commercial site for complex molecules. The stated pilot infrastructure includes 12 reactors with a total capacity of 6,900 litres, plus filter dryers and hydrogenation reactors.

Balance sheet and cash flow: mixed signals behind a “lean balance sheet” narrative

The company’s investor presentation highlights a lean balance sheet as an investment merit. The balance sheet data shows shareholders’ funds at INR 163.02 crore in FY26 versus INR 145.19 crore in FY25. Long-term borrowings reduced to INR 21.25 crore from INR 29.48 crore. At the same time, short-term borrowings increased slightly to INR 9.42 crore from INR 8.76 crore, and trade payables increased to INR 9.44 crore from INR 5.97 crore.

Working capital moved as well. Trade receivables rose to INR 32.57 crore from INR 22.27 crore, and inventories increased to INR 24.01 crore from INR 22.02 crore.

Cash from operating activities declined to INR 23.75 crore in FY26 from INR 30.66 crore in FY25. Net cash flow turned positive in FY26 at INR 2.17 crore versus negative INR 6.05 crore in FY25, aided by lower investing outflow in FY26 (INR -9.89 crore versus INR -35.66 crore in FY25). Cash at year end increased to INR 13.36 crore from INR 9.90 crore.

Dahej: longer-dated optionality for large-scale projects

Beyond Ankleshwar, the company’s Dahej plan is positioned as a platform for large-scale, capital-intensive, highly automated projects with large corporates. The presentation states the company acquired 40,554 square metres of land at Dahej in 2022 with an INR 11 crore outlay.

Management said common utilities and infrastructure construction is ongoing, and that manufacturing expansion at Dahej is intended to be pursued after Ankleshwar capacity is more fully utilised. It also indicated a broad commissioning time frame of about 16 to 20 months once the new plant is taken up.

Takeaways

Shree Ganesh Remedies ended FY26 with a clear message: the year was not designed for aggressive growth, but for groundwork. Q4 FY26 showed improved execution and recovery from deferred shipments, while FY26 reflected margin compression and lower PAT despite flat revenue.

The near-term investment narrative is centred on execution of the transition from CRAMS pilot trials to commercial trials, commissioning and ramp-up of Block 7 from Q2 FY27, and improved demand stability in export markets. At the same time, the company’s own commentary underlines that regulatory approvals, customer registrations, and geopolitics can move timelines. FY27, as management framed it, is expected to be the year where groundwork begins translating into more visible outcomes, but the cadence is likely to be gradual rather than linear.